Male
Multidisciplinary Team(s)
Hematologic (Malignant)
Department/Research Program(s)
Department of Oncology
Cancer Type(s)
Multiple Myeloma
Amyloidosis
Non-Hodgkin's Lymphoma
Leukemia
Plasmacytoma
Contact Info
Email:
zonderj@karmanos.org
来自 http://www.karmanos.org/physicians/Jeffrey-Zonder?Disease=73PageIndex=0SortDirection=1
Education
Fellowship
Hematology/oncology Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Fellowship
Hematology/oncology Chief Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Medical School
Wayne State University School of Medicine
1995
Residency
Primary Care Internal Medicine Residency Program, Strong Memorial Hospital, Rochester, NY
1998
Professional Memberships/Associations
American Society of Hematology
American Society of Clinical Oncology
Southwest oncology Group, Multiple Myeloma and Special Populations Committees
Board Certifications
Michigan State and New York State License
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Clinical Interests
Hematology Oncology
Research Interests
Investigation of new drug application for white cell disorders
Profile
Dr. Zonder has special interest in multidisciplinary care of patients with Multiple Myeloma, as well as other hematologic cancers.In addition, he is focused on the investigation of therapies for Multiple Myeloma.
Awards
2007Wayne State University Division of Hematology-Oncology, Hematology Teaching Attending of the Year
2005Teaching Award, Wayne State University School of Medicine
Publications
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Blood. 2011 Dec 19. [Epub ahead of print] Authors: Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.J Clin Oncol. 2011 Nov 10;29(32):4243-9. Epub 2011 Oct 11. Authors: Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC.
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J. 2011 Mar;41(3):286-8. doi: 10.1111/j.1445-5994.2011.02426.x. Authors: Tageja N, Giorgadze T, Zonder J.
Cancer Patient Fracture evaluation (CAFE) Investigators.Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):225-35. Epub 2011 Feb 16. Authors: Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Bastian L, Ashraf T, Vrionis F;
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a reandomized Southwest oncology Group trial (S0232). Blood. 2010 Dec 23;116(26):5838-41. Epub 2010 Sep 27. Authors: Zonder JA, Crowlet J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, Abidi MH, Durie BG, Barlogie B.
